---
title: How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
date: '2024-10-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39356892/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241003195203&v=2.18.0.post9+e462414
source: Blood
description: Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy,
  but older patients are at higher risk of relapsed disease as they may not be eligible
  for full-intensity frontline chemoimmunotherapy or have comorbidities that limit
  standard treatments. Recent years have brought more treatment options than ever
  for this patient population, but it remains challenging to determine which can be
  safely and effectively offered to older patients. Formal determinations of ...
disable_comments: true
---
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, but older patients are at higher risk of relapsed disease as they may not be eligible for full-intensity frontline chemoimmunotherapy or have comorbidities that limit standard treatments. Recent years have brought more treatment options than ever for this patient population, but it remains challenging to determine which can be safely and effectively offered to older patients. Formal determinations of ...